^
Association details:
| Biomarker: | HER-2 positive + CAV1 overexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Caveolin-1 modulation improves Trastuzumab Emtansine (TDM1) efficacy in HER2-overexpressing gastric cancer
Published date:
05/28/2021
Excerpt:
HER2+ GC samples from patients who underwent trastuzumab therapy were evaluated for CAV1 expression by immunohistochemistry...patients with HER2+/CAV1HIGH (29.4% of total HER2+ GC) have a significantly worse overall survival than those expressing low CAV1....
